Protica Bio integrates cutting-edge proteomics with machine learning to address significant unmet needs in immunotherapy.
The company’s technology, already yielding promising clinical results, leads to the identification of resistance mechanisms which limit the effectiveness of current therapies, enabling personalized medicine and informed therapeutic decision making. The technology also serves as a platform for discovery of novel drug targets.
CEO: Olga Nissan, PhD